Aptose Reports Results for the Third Quarter 2024
Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly ...
Researchers identify six-gene pattern to predict drug success in multiple myeloma patients
Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, ...
The American Journal of Managed Care3d
Venetoclax May Be an Option for Children With R/R AML, MDS
The single-center report showed the therapy had a favorable safety profile and manageable side effects in children with ...
Oncology Nurse Advisor3d
Relapsed/Refractory CLL: Which Treatments Are the Safest?
Researchers found no significant differences in the risk of overall adverse events (AEs), but there were significant differences in grade 3 or higher AEs, serious AEs, treatment discontinuations due ...
PharmiWeb4d
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation
Aptevo's Peter Pavlik, PhD, to chair a session on "Bi and Multispecific Biologics" and will also give talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR™ ...
The American Journal of Managed Care4d
Real-World Data Confirm Ibrutinib's Role in Relapsed CLL
This multiyear follow-up of more than 3300 patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who ...
ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Annual Meeting
ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Annual ...